Please login to the form below

Not currently logged in
Email:
Password:

Dry eye disease

This page shows the latest Dry eye disease news and features for those working in and with pharma, biotech and healthcare.

Ipsen buys rare disease group Clementia in $1.3bn deal

Ipsen buys rare disease group Clementia in $1.3bn deal

Will acquire lead multiple rare disease candidate palovarotene. Ipsen is set to pay out a total of $1.3bn to buy Clementia Pharmaceuticals in a move that will significantly boost its ... Alongside its potential in FOP and MO, for which palovarotene has

Latest news

  • Shire files dry eye drug lifitegrast in Europe Shire files dry eye drug lifitegrast in Europe

    Analysts predict Xiidra could become a $1bn product. Shire is awaiting the go-ahead of lifitegrast in the EU, seeking approval for the would-be dry eye disease blockbuster. ... Dry eye disease causes discomfort, stinging and blurry vision, and can

  • Shire licences Parion dry eye drug in $535m deal Shire licences Parion dry eye drug in $535m deal

    Parion has already completed a phase I/II trial in 53 patients with mild-to-moderate dry eye disease with preliminary signs that it could improve symptoms. ... This is an opportunity to apply our knowledge and experience from ophthalmics and dry eye

  • Shire launches dry eye drug Xiidra in US Shire launches dry eye drug Xiidra in US

    Shire's recently-approved dry eye disease drug Xiidra is now available in the US, throwing down a challenge to Allergan's rival therapy Restasis. ... Some analysts believe the product could actually benefit from the increased awareness of dry eye disease

  • FDA finally approves Shire’s potential blockbuster Xiidra FDA finally approves Shire’s potential blockbuster Xiidra

    year. Allergan's Restasis (cyclosporine ophthalmic emulsion) is the major player in dry eye disease – but Shire will hope that it can quickly establish a considerable foothold. ... adds. Dry eye disease is caused by a reduced ability to produce tears

  • FDA deals a big blow to Shire's late-stage pipeline FDA deals a big blow to Shire's late-stage pipeline

    Additional data required before firm can apply for re-approval. Shire suffered a major setback last week when the FDA declined to approve its lifitegrast treatment for dry eye disease, which ... Dry eye disease is caused by a reduced ability to produce

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    However, ophthalmology is increasingly an area of interest in the industry with potential for growth as the global population ages; it is estimated that around 25m people have dry eye disease ... 175. SARcode Bioscience/ Shire. Acquisition. SAR 1118 for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics